Home / News and Insights / News / Bircham Dyson Bell advises ImmuPharma PLC on its £10 million fundraising
25 January 2018

Bircham Dyson Bell advises ImmuPharma PLC on its £10 million fundraising

Bircham Dyson Bell acted for ImmuPharma PLC, the AIM-listed specialist drug discovery and development company, in relation to its fundraising, which raised £10 million by way of a share subscription and placing with new and existing shareholders.

The transaction was led by corporate partner Philip Lamb and senior associate Tessa Trevelyan Thomas.

Philip Lamb comments:

‘We are delighted by the successful outcome of this fundraising at an exciting stage of the company’s development, and to be continuing our long-standing relationship with the company dating back to before it floated in 2006.’

Related Articles